Healthcare - Biotechnology - NASDAQ - US
$ 1.56
-8.77 %
$ 75.4 M
Market Cap
-1.07
P/E
CASH FLOW STATEMENT
-104 M
OPERATING CASH FLOW
-98 K
INVESTING CASH FLOW
77 K
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
BioAtla, Inc.
| Net Income | -123 M |
| Depreciation & Amortization | 1.22 M |
| Capital Expenditures | -98 K |
| Stock-Based Compensation | 13.5 M |
| Change in Working Capital | 4.68 M |
| Others | -602 K |
| Free Cash Flow | -104 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (123.5) | (106.5) | (95.4) | (35.9) | (29.9) | (29.0) |
| Depreciation & Amortization | 1.2 | 1.2 | 1.3 | 1.0 | 0.9 | 0.8 |
| Deferred Income Tax | 0 | 0 | (0.7) | 4.5 | 6.4 K | 0 |
| Stock Based Compensation | 13.5 | 14.6 | 25.1 | 3.0 | 6.4 K | 2.64 K |
| Other Operating Activities | 2 K | 13 K | 3 K | (6.5) | (5.8) | 2.6 |
| Change in Working Capital | 4.7 | 0.3 | 7.4 | (2.5) | 25.1 | (9.7) |
| Cash From Operations | (104.0) | (90.4) | (62.2) | (36.3) | (9.6) | (35.3) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 98 K | (0.3) | (0.9) | (0.6) | (1.5) | (1.0) |
| Other Items | 0 | 3 K | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 98 K | (0.3) | (0.9) | (0.6) | (1.5) | (1.0) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 259 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 3.4 | 4.0 | 5.0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 77 K | (0.5) | (1.5) | 68.2 | 5 K | 19 K |
| Cash From Financing Activities | 77 K | 61.2 K | 69.5 | 271.8 | 4.0 | 5.0 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (104.0) | (29.5) | 6.4 | 234.9 | (7.2) | (31.3) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (104.1) | (90.7) | (63.1) | (36.9) | (11.2) | (36.3) |